Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 6 September 1985:
Vol. 229. no. 4717, pp. 976 - 978
DOI: 10.1126/science.2992090
Prev | Table of Contents | Next

Articles

Science, Vol 229, Issue 4717, 976-978
Copyright © 1985 by American Association for the Advancement of Science

articles

The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor

AL Schechter, MC Hung, L Vaidyanathan, RA Weinberg, TL Yang-Feng, U Francke, A Ullrich, and L Coussens

The neu oncogene, identified in ethylnitrosourea-induced rat neuroglioblastomas, had strong homology with the erbB gene that encodes the epidermal growth factor receptor. This homology was limited to the region of erbB encoding the tyrosine kinase domain. It was concluded that the neu gene is a distinct novel gene, as it is not coamplified with sequences encoding the EGF receptor in the genome of the A431 tumor line and it maps to human chromosome 17.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Trastuzumab in the Adjuvant Treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
I. J. Dahabreh, H. Linardou, F. Siannis, G. Fountzilas, and S. Murray (2008)
Oncologist 13, 620-630
   Abstract »    Full Text »    PDF »
HER-2/neu transcriptionally activates Jab1 expression via the AKT/{beta}-catenin pathway in breast cancer cells.
M.-C. Hsu, H.-C. Chang, and W.-C. Hung (2007)
Endocr. Relat. Cancer 14, 655-667
   Abstract »    Full Text »    PDF »
Meeting Report: Barossa 2005--Signaling Networks.
M. A. Guthridge, G. J. Goodall, and S. M. Pitson (2006)
Sci. STKE 2006, pe9
   Abstract »    Full Text »    PDF »
Expression of HER2 and the Coamplified Genes GRB7 and MLN64 in Human Breast Cancer: Quantitative Real-time Reverse Transcription-PCR as a Diagnostic Alternative to Immunohistochemistry and Fluorescence In situ Hybridization.
U. Vinatzer, B. Dampier, B. Streubel, M. Pacher, M. J. Seewald, C. Stratowa, K. Kaserer, and M. Schreiber (2005)
Clin. Cancer Res. 11, 8348-8357
   Abstract »    Full Text »    PDF »
Trastuzumab in the treatment of breast cancer..
G. N. Hortobagyi (2005)
N. Engl. J. Med. 353, 1734-1736
   Full Text »    PDF »
Bcl-2 Antisense Oligonucleotide Overcomes Resistance to E1A Gene Therapy in a Low HER2-Expressing Ovarian Cancer Xenograft Model.
C. Bartholomeusz, H. Itamochi, L. X.H. Yuan, F. J. Esteva, C. G. Wood, N. Terakawa, M.-C. Hung, and N. T. Ueno (2005)
Cancer Res. 65, 8406-8413
   Abstract »    Full Text »    PDF »
Comparison of Two Quantitative Polymerase Chain Reaction Methods for Detecting HER2/neu Amplification.
A. Millson, A. Suli, L. Hartung, S. Kunitake, A. Bennett, M. C. L. Nordberg, W. Hanna, C. T. Wittwer, A. Seth, and E. Lyon (2003)
J. Mol. Diagn. 5, 184-190
   Abstract »    Full Text »    PDF »
Human Epidermal Receptor-2 Expression in Prostate Cancer.
B. F. Calvo, A. M. Levine, M. Marcos, Q. F. Collins, M. V. Iacocca, L. S. Caskey, C. W. Gregory, Y. Lin, Y. E. Whang, H. S. Earp, et al. (2003)
Clin. Cancer Res. 9, 1087-1097
   Abstract »    Full Text »    PDF »
Active Signaling by HER-2/neu in a Subpopulation of HER-2/neu-overexpressing Ductal Carcinoma in Situ: Clinicopathological Correlates.
M. P. DiGiovanna, P. Chu, T. L. Davison, C. L. Howe, D. Carter, E. B. Claus, and D. F. Stern (2002)
Cancer Res. 62, 6667-6673
   Abstract »    Full Text »    PDF »
c-erb B-2 Expression Is Associated with Tumor Location and Venous Invasion and Influences Survival of Patients with Gastric Carcinoma.
J. Pinto-de-Sousa, L. David, R. Almeida, D. Leitao, J. R. Preto, M. Seixas, and A. Pimenta (2002)
International Journal of Surgical Pathology 10, 247-256
   Abstract »    PDF »
Relationship of Serum HER-2/neu and Serum CA 15-3 in Patients with Metastatic Breast Cancer.
S. M. Ali, K. Leitzel, V. M. Chinchilli, L. Engle, L. Demers, H. A. Harvey, W. Carney, J. W. Allard, and A. Lipton (2002)
Clin. Chem. 48, 1314-1320
   Abstract »    Full Text »    PDF »
Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2-Overexpressing Metastatic Breast Cancer.
F. J. Esteva, V. Valero, D. Booser, L. T. Guerra, J. L. Murray, L. Pusztai, M. Cristofanilli, B. Arun, B. Esmaeli, H. A. Fritsche, et al. (2002)
J. Clin. Oncol. 20, 1800-1808
   Abstract »    Full Text »    PDF »
Elevated Serum HER-2/neu Level Predicts Decreased Response to Hormone Therapy in Metastatic Breast Cancer.
A. Lipton, S.M. Ali, K. Leitzel, L. Demers, V. Chinchilli, L. Engle, H. A. Harvey, C. Brady, C.M. Nalin, M. Dugan, et al. (2002)
J. Clin. Oncol. 20, 1467-1472
   Abstract »    Full Text »    PDF »
Early Placenta Insulin-like Growth Factor (pro-EPIL) Is Overexpressed and Secreted by c-erbB-2-positive Cells with High Invasion Potential.
B. Brandt, A. Roetger, J.-M. Bidart, J. Packeisen, K. Schier, J.-H. Mikesch, D. Kemming, W. Boecker, D. Yu, and H. Buerger (2002)
Cancer Res. 62, 1020-1024
   Abstract »    Full Text »    PDF »
Identification of a Heregulin Binding Site in HER3 Extracellular Domain.
E. Singer, R. Landgraf, T. Horan, D. Slamon, and D. Eisenberg (2001)
J. Biol. Chem. 276, 44266-44274
   Abstract »    Full Text »    PDF »
The Prognostic and Predictive Values of ECD-HER-2.
W. N. Hait (2001)
Clin. Cancer Res. 7, 2601-2604
   Abstract »    Full Text »    PDF »
Segment-Specific c-ErbB2 Expression in Human Autosomal Recessive Polycystic Kidney Disease.
K. NAKANISHI, W. E. SWEENEY JR., and E. D. AVNER (2001)
J. Am. Soc. Nephrol. 12, 379-384
   Abstract »    Full Text »
Identification and Characterization of an Activating TrkA Deletion Mutation in Acute Myeloid Leukemia.
G. W. Reuther, Q. T. Lambert, M. A. Caligiuri, and C. J. Der (2000)
Mol. Cell. Biol. 20, 8655-8666
   Abstract »    Full Text »    PDF »
The Association of HER-2/neu Amplification With Breast Cancer Recurrence.
J. A. Carr, S. Havstad, R. J. Zarbo, G. Divine, P. Mackowiak, and V. Velanovich (2000)
Arch Surg 135, 1469-1474
   Abstract »    Full Text »    PDF »
E1A-mediated Paclitaxel Sensitization in HER-2/neu-overexpressing Ovarian Cancer SKOV3.ip1 through Apoptosis Involving the Caspase-3 Pathway.
N. T. Ueno, C. Bartholomeusz, J. L. Herrmann, Z. Estrov, R. Shao, M. Andreeff, J. Price, R. W. Paul, P. Anklesaria, D. Yu, et al. (2000)
Clin. Cancer Res. 6, 250-259
   Abstract »    Full Text »
Combination of EGFR, HER-2/neu, and HER-3 Is a Stronger Predictor for the Outcome of Oral Squamous Cell Carcinoma Than Any Individual Family Members.
W. Xia, Y.-K. Lau, H.-Z. Zhang, F.-Y. Xiao, D. A. Johnston, A.-R. Liu, L. Li, R. L. Katz, and M.-C. Hung (1999)
Clin. Cancer Res. 5, 4164-4174
   Abstract »    Full Text »    PDF »
c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells.
B. H. BRANDT, A. ROETGER, T. DITTMAR, G. NIKOLAI, M. SEELING, A. MERSCHJANN, J.-R. NOFER, G. DEHMER-MÖLLER, R. JUNKER, G. ASSMANN, et al. (1999)
FASEB J 13, 1939-1949
   Abstract »    Full Text »
Predictive Value of c-erbB-2 and Cathepsin-D for Greek Breast Cancer Patients Using Univariate and Multivariate Analysis.
A. Scorilas, J. Yotis, C. Pateras, T. Trangas, and M. Talieri (1999)
Clin. Cancer Res. 5, 815-821
   Abstract »    Full Text »    PDF »
Mitosis-specific Negative Regulation of Epidermal Growth Factor Receptor, Triggered by a Decrease in Ligand Binding and Dimerization, Can Be Overcome by Overexpression of Receptor.
N. Kiyokawa, E. K. Lee, D. Karunagaran, S.-Y. Lin, and M.-C. Hung (1997)
J. Biol. Chem. 272, 18656-18665
   Abstract »    Full Text »    PDF »
Differential Expression of the erbB2 Gene in the Periimplantation Mouse Uterus: Potential Mediator of Signaling by Epidermal Growth Factor-Like Growth Factors.
H. Lim, S. K. Dey, and S. K. Das (1997)
Endocrinology 138, 1328-1337
   Abstract »    Full Text »    PDF »
c-erbB-2 Oncoprotein Immunoreactivity in Gallbladder and Biliary Tract Cancers.
C. S. Lee and A. Pirdas (1996)
International Journal of Surgical Pathology 4, 71-76
   Abstract »    PDF »
In Reply: Amplification c-erbB-2 and Aggressive Human Breast Tumors?.
D. J. Slamon and G. M. Clark (1988)
Science 240, 1796-1798
   PDF »
erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.
P. Di Fiore, J. Pierce, M. Kraus, O Segatto, C. King, and S. Aaronson (1987)
Science 237, 178-182
   Abstract »    PDF »
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D. Slamon, G. Clark, S. Wong, W. Levin, A Ullrich, and W. McGuire (1987)
Science 235, 177-182
   Abstract »    PDF »
In Vitro Models for Studying the Molecular Biology of Carcinogenesis.
J. A. DiPaolo, A. Burkhardt, J. Doniger, L. Pirisi, N. C. Popescu, and S. Yasumoto (1986)
Toxicol Pathol 14, 417-423
   Abstract »    PDF »
Chromosomal Mapping of Genes Involved in Growth Control.
U. Francke, T.L. Yang-Feng, J.E. Brissenden, and A. Ullrich (1986)
Cold Spring Harb Symp Quant Biol 51, 855-866
   Abstract »    PDF »
Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.
L Coussens, T. Yang-Feng, Y. Liao, E Chen, A Gray, J McGrath, P. Seeburg, T. Libermann, J Schlessinger, U Francke, et al. (1985)
Science 230, 1132-1139
   Abstract »    PDF »
Constitutive Tyrosine Phosphorylation of ErbB-2 via Jak2 by Autocrine Secretion of Prolactin in Human Breast Cancer.
T. Yamauchi, N. Yamauchi, K. Ueki, T. Sugiyama, H. Waki, H. Miki, K. Tobe, S. Matsuda, T. Tsushima, T. Yamamoto, et al. (2000)
J. Biol. Chem. 275, 33937-33944
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)